At what enterprise value was VETONE acquired in 2021?

During the acquisition of VETONE by IVC EVIDENSIA in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of VETONE when it was acquired by IVC EVIDENSIA?

The estimated EV/EBITDA multiple for VETONE is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was VETONE acquired by IVC EVIDENSIA?

VETONE was acquired by IVC EVIDENSIA in 2021.

What was the revenue of VETONE at the time of the deal?

The revenue of VETONE at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of VETONE during the acquisition?

VETONE's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the VETONE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the VETONE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/build-up/ivc-evidensia-soffre-les-cliniques-veterinaires-vetone-1358964

← DATABASE

Home Database Healthcare & PharmaVETONE

10/2021

VETONE acquired by IVC EVIDENSIA

FRANCE Health Providers / Outpatient Care / Vet Clinics EV 100M - 350M EUR

Context

IVC Evidensia acquired VetOne in a preemptive move to consolidate its leadership in the French market. The deal successfully bypassed a planned auction process due to a high-premium offer. The transaction provided an exit for VetOne's shareholders, including the founder, practicing veterinarians, and various private investors. The strategic rationale was to integrate VetOne's 51 clinics with IVC's existing French footprint, creating a dominant national player. The investment thesis is supported by low market consolidation in France and significant upside in ancillary services such as pet insurance, specialized medication, and premium pet food sales.

VETONE, which reported an EBITDA margin of in 2021, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2013 by Steve Rosengarten, VetOne is a high-growth operator of veterinary clinics in France. At the time of the deal, the group managed a network of 51 clinics, following an aggressive acquisition strategy of 2 to 3 clinics per month. The company serves as a strategic consolidation platform in the fragmented French veterinary market.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2021	VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT	VIVALTO SANTÉ	FRANCE	Clinics / Hospitals
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Labs (Biology)
10/2021	ARES / BPIFRANCE	POINT VISION	FRANCE	Ophthalmology
10/2021	THE CRANEMERE GROUP	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology
09/2021	LIVINGBRIDGE	EVERLIGHT RADIOLOGY	UNITED KINGDOM	Radiology
08/2021	COLOSSEUM DENTAL GROUP	CURAEOS	NETHERLANDS	Dental Centers
07/2021	CERBA HEALTHCARE	LIFEBRAIN	ITALY	Labs (Biology)
07/2021	OMERS	AMEDES	GERMANY	Labs (Biology)
07/2021	EQT PARTNERS	MEINE RADIOLOGIE	GERMANY	Radiology
07/2021	WREN HOUSE	ALMAVIVA SANTÉ	FRANCE	Clinics / Hospitals

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VETONE by IVC EVIDENSIA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.